PCLAF

Across TCGA pan-cancer cohorts, PCLAF mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PCLAF data layer compared with 28 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PCLAF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCLAF expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC are the cancer types where PCLAF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	All	1.000	0.818	.033	4	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PCLAF–UCEC (DFS)

Open the UCEC breakdown →